Perioperative Pharmacokinetic/Pharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery (PROPHTAZ)
PROPHTAZ: Evaluation of Pharmacokinetic/Pharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery, a Prospective Observational Pharmacokinetic Study
Hepatic and pancreatic surgeries are associated with a high risk of surgical site infections, particularly in patients with preoperative biliary drainage, which is frequently associated with bacterial colonization of bile. In this context, perioperative antibiotic prophylaxis is essential, and recent guidelines recommend the use of piperacillin/tazobactam in selected high-risk patients.
However, piperacillin, like other β-lactam antibiotics, exhibits pharmacokinetic variability that may be exacerbated during major surgery due to factors such as fluid shifts, hypoalbuminemia, and changes in volume of distribution. These alterations may result in suboptimal antibiotic exposure during the perioperative period, potentially compromising prophylactic efficacy.
Despite these concerns, standard dosing regimens remain unchanged across different types of major abdominal surgery, including hepatic and pancreatic procedures, which differ significantly in terms of duration, physiological impact, and intraoperative management.
The PROPHTAZ study is a prospective, single-center observational pharmacokinetic study designed to evaluate whether standard perioperative administration of piperacillin/tazobactam achieves predefined pharmacokinetic/pharmacodynamic (PK/PD) targets in patients undergoing hepatic or pancreatic surgery. The primary objective is to determine the proportion of patients achieving adequate PK/PD exposure during surgery. Secondary objectives include describing perioperative plasma concentrations, assessing pharmacokinetic variability, identifying factors associated with target non-attainment, and comparing outcomes between surgical subgroups.
This study aims to provide clinically relevant data to assess the adequacy of current prophylactic dosing strategies and to support potential optimization of antibiotic administration in high-risk surgical patients.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Emmanuel NOVY, MD, PhD
- 电话号码:+33 383157437
- 邮箱:e.novy@chru-nancy.fr
学习地点
-
-
-
Nancy、法国
- 招聘中
- CHRU de NANCY
-
-
Lorraine
-
Vandœuvre-lès-Nancy、Lorraine、法国、54500
- 尚未招聘
- CHRU de Nancy
-
接触:
- Viviane MARTIN, PhD
- 电话号码:+33 3155285
- 邮箱:v.martin3@chru-nancy.fr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study population consists of adult patients undergoing elective hepatic or pancreatic surgery at a tertiary care university hospital (CHRU Nancy, France). Eligible patients are those receiving perioperative antibiotic prophylaxis with piperacillin/tazobactam according to current clinical guidelines, particularly in the context of preoperative biliary drainage or high risk of biliary contamination.
These patients represent a high-risk surgical population for surgical site infections, characterized by complex procedures, potential intraoperative hemodynamic variations, and significant pharmacokinetic variability. Patients are managed in a perioperative setting including the operating room and postoperative admission to a surgical intensive care or intermediate care unit.
描述
Inclusion Criteria:
- Adults > or = to 18 years old
- Scheduled for major hepatic or pancreatic surgery
- Receiving piperacillin/tazobactam as perioperative antibiotic prophylaxis according to guidelines
Exclusion Criteria:
- decline to participate
- Known allergy of beta-lactam
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Adult patients with scheduled pancreatic or major hepatic surgery
Adult patients with scheduled pancreatic surgery or major hepatic receiving piperacillin/tazobactam as antibiotic prophylaxis |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PK/PD target attainment of piperacillin
大体时间:4 hours after the administration of piperacillin
|
Proportion of patients achieving the predefined* PK/PD target during the perioperative period *estimated free concentration of piperacillin (80% of the total concentration) above the MIC of the isolated pathogen from bile samples throughout the surgical procedure (from incision to wound closure) |
4 hours after the administration of piperacillin
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma piperacillin concentration
大体时间:4 hours after the administration of piperacillin
|
Total (measured) et free (estimated) concentration of piperacilline throughout at two timepoints: surgical incision and wound closure |
4 hours after the administration of piperacillin
|
|
Factors associated with target attainment
大体时间:4 hours after the administration of piperacillin
|
Analysis of clinical and biological covariates associated with pharmacokinetic variability and the achievement of pharmacodynamic targets |
4 hours after the administration of piperacillin
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2025PI208
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.